The COVID-19 crisis changed the way people work across industries including the pharma industry. MD Analytics teamed up with the professional association for women in the pharma industry Women Leaders in Pharma to conduct a study on the impact on of COVID-19 on women who work in the pharma industry.
As the COVID-19 vaccination campaign ramped up in the Spring, and rates of infection dropped, a return to normality appeared to be on the horizon. However, with widespread vaccine hesitancy paired with the virulent spread of the delta variant, we are once again left with an uncertain view of the future.
Throughout the past year, MD Analytics has been monitoring the effects of this uncertainty, and the pandemic in general, on the practices and perceptions of HCPs. Ongoing changes in workloads, patient assessments, and interactions with pharma have had direct and meaningful impact on the healthcare industry.
The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward?
Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19 since the start of the pandemic. It also delves into the changes in the modes of interactions with both patients and the pharmaceutical industry. Continue reading and check out our infographic to learn more about how HCPs have been impacted and what changes are here to stay.
Virtual medical conferences are on the rise, but are they here to stay?
As a result of the pandemic over the past year, conference organizers and medical brands were set scrambling to find a solution to limit cancelations of key medical conferences. Resulting virtual platforms advanced quickly to emulate the face-to-face conference experience through a digital means. While many virtual medical conferences were successful, in terms of strong participation levels to many key events both national and international, questions remained as to how well they met the needs of physicians, other healthcare providers and the pharmaceutical and medical device companies sponsoring these events.
The detailing of healthcare providers through virtual means has become a staple for pharmaceutical brands and is essential for any go-to-market strategy. When face-to-face detailing was put on hold this past year, healthcare providers began experiencing an even greater volume of requests for virtual interactions. For pharma brand teams, ensuring your approach to digital communications matches with the preferences of providers is important in helping your messages get through to your target prescribers.
In our latest quick poll, conducted in March 2021, MD Analytics sought to gain clarity around current remote detailing preferences and identify the components of an “ideal” remote interaction.
Each year, providers and health industry professionals travel from locations around the world to share and discuss the latest developments in medical care. For several years now, conferences have been experimenting with digital features that allow participants to engage remotely, avoiding the burdens of travel. However, the scope of content available to digital participants had often been limited and physician adoption was low.
Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.
The COVID-19 crisis has significantly impacted physicians’ practices; but how and to what extent? Physicians have been managing significant workloads, while learning on the fly how to navigate and setup virtual meetings. Maintaining high levels of patient care while minimizing in-person interactions has also been challenging.
Strong online advertising and messaging are key to maximizing impact of any marketing campaign. With recent restrictions on in-person interactions, online advertising and messaging play an even greater role in reaching physicians. Our findings from a survey of n=227 Canadian physicians show that 82% of Canadian physicians have increased their use of online platforms as a result of COVID-19, 48% significantly so.
Physicians recognize that new medications often can be quite valuable for their patients and are eager to add them to their armamentarium. However, they do not always end up prescribing these new medications as much as they initially plan or as early as they would like. There are many reasons that can explain this discrepancy.
Patients are an increasingly influential stakeholder within the healthcare industry as more medical information becomes available online than ever before. This independent market research study conducted by MD Analytics takes a closer look at patients in order to better understand their motivations and predict their behaviours within this complex landscape.
Physicians are using social media in their personal and professional lives, especially younger physicians. However, the pharma industry should be aware of barriers to using social media as a means of interacting professionally with physicians, such as the perceived reliability of online information.
In October 2018, the use of recreational cannabis was legalized across Canada. Looking back at the past year, physicians remain divided in their views towards this new legislation, though support skews towards younger GPs. This legislation has impacted the use of prescription treatments and patient visits in a number of key therapeutic areas, though not to the degree that was anticipated 12 months ago.
Measuring customer engagement in pharmaceutical market research can be challenging as physicians usually prefer to not be seen as “associated” with any given pharmaceutical company. However, as demonstrated by our customer engagement syndicated study, it is undeniable that stronger levels of physician engagement exist among pharmaceutical companies which can lead to more positive outcomes for their associated brands.
Real World Evidence (RWE) is a growing area of research that, pivoting from the rigorously controlled standards of randomized controlled trials (RCT), is based on a model driven by real world patient data. Real World Evidence stems primarily from an observational analysis of a sample in a less controlled environment. Focused on the efficacy and outcomes of therapies in a real world setting, RWE provides a unique lens not attainable from traditional clinical trial research.
In the healthcare system, a patient’s journey to optimal care presents many obstacles. There are numerous steps involved from the onset of a medical condition to the moment when satisfactory results are achieved. This healthcare survey seeks to reveal key opportunities within the patient journey that would assist patients along their way and ultimately improve outcomes. Further healthcare market research could also be conducted by disease area to dig deeper into these insights.
Over a 3-day period, MD Analytics surveyed 1,000 Canadians that are responsible for making health-related decisions. It was found that respondents are often choosing to not to see a physician when health-related scenarios arise, citing self-diagnosis or lack of convenience as their key reasons. Respondents are also strongly likely to visit a walk-in clinic instead of their family physician, with convenience again mentioned as the key reason.
Qualitative research can provide a greater understanding of physicians’ attitudes and behaviours than quantitative methodologies, however increased demands on physician time may cause some to refuse participating. Determining the optimal study design and appropriate recruitment techniques can help make physicians more willing to participate.